moneyheap
FTH · Analysis updated Nov 10, 2026, 4:50 PM ET
Why is Faeth Therapeutics, Inc. (FTH) stock moving?
Faeth fell 42.49% to $12.68 on Nov 9, on volume of about 4.05M shares against a typical 200K-600K. The drop came after Phase 2 PIK-201 data for PIKTOR plus paclitaxel in endometrial cancer. The data showed a 33% confirmed ORR (12 of 36), an 83% disease control rate, 7.4 months median PFS and mostly low-grade toxicity. The market had apparently expected a higher response rate, and Baird noted pushback on the data. Analysts stayed supportive, with Baird, TD Cowen, Citizens and Cantor reiterating positive ratings and targets of $40-$69, far above the price. On Nov 10 the stock traded in a $11.83-$13.93 range and closed at $12.92, up about 1.9%. Volume was 1.38M, so the post-crash level has held with some stabilization. Cash of $174.8M, Fast Track designation and Phase 3 planning are supports. Breast cancer data are not expected until 2027, so there is no near-term catalyst. Risks include continued net losses, trial dilution or financing needs, and possible further selling from investors who bought ahead of the data.
News behind the analysis
- Faeth stock sinks on phase II data with Piktor in endometrial cancerShares fell about 50% intraday on topline Phase 2 data for Piktor plus paclitaxel in endometrioid endometrial cancer. The response rate was 33% and the disease control rate was 83%.
- Faeth Therapeutics reports positive Phase 2 results for endometrial cancer drugThe confirmed ORR was 33% (12 of 36). Patients with a PIK3CA mutation had a 44% response rate, median PFS was 7.4 months, and the company plans to move toward Phase 3.
- Faeth's phase 2 data power oral combo forward in cancer targeted by ADC heavyweightsFaeth says the data clear the Phase 2 efficacy bar for an oral therapy in a field dominated by injectables. Breast cancer data are expected next year.
- Faeth Therapeutics stock maintained at Buy by TD Cowen on trial dataTD Cowen kept its Buy rating and said the mechanism supports Phase 3 development. Citizens kept Market Outperform with a $51 target.
- Baird reiterates Faeth Therapeutics stock rating on clinical dataBaird sees the data supporting Phase 3 planning and a positive read-through to breast cancer. Analyst targets range from $40 to $69.
- Baird reiterates Faeth Therapeutics stock rating on PIK-201 dataBaird addressed pushback on the data and called PIK-201 a key validation point. The stock was at $12.79, down 35% over the past week.
- Faeth's combo posts mid-stage refractory endometrial cancer winPatients were heavily pretreated, with a median of two prior lines. 7% discontinued due to adverse events and there were no drug-related deaths.
- FTH: Faeth Therapeutics Inc. filed SEC Form 8-KFaeth made a corporate presentation with the PIK-201 topline data available on Nov 9. The 8-K itself does not summarize the results.
- Faeth Therapeutics stock: PIKTOR data due by year-endQ3 results on Nov 3 showed $174.8M in cash and securities at Sep 30. PIKTOR also has FDA Fast Track designation.